title: Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.
abstract: Fibrates, the PPAR alpha ligand-like compounds increase the expression of proximal tubule liver fatty acid binding protein (L-FABP) and significantly decrease cisplatin-induced acute kidney injury. To study whether the bezafibrate-mediated upregulation of renal L-FABP was involved in this cytoprotective effect we treated transgenic mice of PPAR agonists inducible human L-FABP expression with cisplatin in the presence or absence of bezafibrate. Blood urea nitrogen was unchanged in the first day but increased 3 days after cisplatin. While urinary L-FABP increased over 100-fold 1 day after cisplatin treatment in the transgenic mice it was significantly reduced when these transgenic mice were pretreated with bezafibrate. Cisplatin-induced renal necrosis and apoptosis were significantly reduced in bezafibrate pretreated transgenic mice and this correlated with decreased accumulation of lipid and lipid peroxidation products. Immunohistochemical analysis of kidney tissue of bezafibrate-cisplatin-treated transgenic mice showed preservation of cytoplasmic L-FABP in the proximal tubule, but this was reduced in transgenic mice treated only with cisplatin. L-FABP mRNA and protein levels were significantly increased in bezafibrate-cisplatin-treated transgenic mice when compared to mice not fibrate treated. Our study shows that the bezafibrate-mediated upregulation of proximal tubule L-FABP plays a pivotal role in the reduction of cisplatin-induced acute kidney injury.
authors: Department of Nephrology and Endocrinology, Hemodialysis and Apheresis, University Hospital, University of Tokyo, Tokyo, Japan.
authors: K
authors: K
authors: Negishi
authors: E
authors: E
authors: Noiri
authors: R
authors: R
authors: Maeda
authors: D
authors: D
authors: Portilla
authors: T
authors: T
authors: Sugaya
authors: T
authors: T
authors: Fujita
mesh_terms: D000818:Animals; D017209:Apoptosis; D001629:Bezafibrate / Q000494:pharmacology*; D002945:Cisplatin / Q000633:toxicity; D019610:Cytoprotection; D050556:Fatty Acid-Binding Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control*; D015227:Lipid Peroxidation / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D009336:Necrosis; D047493:PPAR alpha / Q000819:agonists; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C493319:FABP1 protein, human; D050556:Fatty Acid-Binding Proteins; D047493:PPAR alpha; D012333:RNA, Messenger; D002945:Cisplatin; D001629:Bezafibrate